BDCM, SSOL and GNTA are the Stocks to Watch for June 6th from OTCPicks.com

Dallas, TX – LOCATI GLOBAL HOLDINGS / BROADCAST MARKETING (OTC: BDCM) "Up 542.86% on Monday"
LoCatI Global Holdings, LLC / Broadcast Marketing Group, Inc. is acquiring the technology and assets with the intention of providing a more sophisticated mechanism for tracking items of value. The strategy is to offer a fee-based license with companies that are already mimicking or attempting to mimic the claims in the patent and possibly form a partnership with one specific company to ensure compliance from all competitors.

SUNVALLEY SOLAR INCORPORATED (OTCBB: SSOL) "Up 95.06% on Monday"
Sunvalley Solar, Inc. is a leading solar system solution provider that offers comprehensive solar energy technology, system design, installation, equipments, and technical support for electrical contractors, builders, homeowners, businesses/commercial buildings, and government entities that assist them in lowering of utility bills, reducing environmental impacts, and increasing energy reliability and independence through solar energy. Located in Los Angeles, California, Sunvalley Solar, Inc. is committed to reducing the world's carbon foot print from traditional energy sources to make renewable sources such as solar the nation's mainstream source of power.

GENTA INCORPORATED (OTCBB: GNTA) "Up 62.30% on Monday"
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company is developing tesetaxel, a novel, orally absorbed taxane that is in the same class of drugs as paclitaxel and docetaxel. As the leading oral taxane in clinical development, tesetaxel has been evaluated in a broad program of completed or ongoing Phase 2a/Phase 2b clinical trials. The Company has announced that gastric (stomach) cancer will be the lead indication for Phase 3 registration studies. Genasense® (oblimersen sodium) Injection is a modified DNA-based antisense drug that may enhance the effectiveness of anticancer therapy. Genta has completed enrollment in a randomized, double-blind Phase 3 study of Genasense® in patients with advanced melanoma, known as “AGENDA”. Final data on survival and durable response from AGENDA, which may be pivotal for regulatory approval, are expected in the first half of 2011. Genta is exclusively marketing Ganite® (gallium nitrate injection) in the U.S., which is indicated for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has developed proprietary oral formulations of the active ingredient in Ganite® that are being evaluated as potential treatments for diseases associated with accelerated bone loss. Ganite® and Genasense® are available on a “named-patient” basis in countries outside the United States.

About OTCPicks.com

OTCPicks.com, one of the leading penny stock Web sites, presents its daily Stocks to Watch and Midday Market Movers every weekday. In addition to all the latest penny stock news, OTCPicks also offers daily newsletters, unique commentaries and free profiles, alerts and investing tips.

The stocks presented above are available in OTCPicks.com's Free Daily Email Newsletter. For daily penny stock alerts CLICK HERE.

Disclosure: OTCPicks.com has not been compensated by any of the companies covered in this release.